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The relationship between anabolic-androgenic steroid (AAS) use and aggression and
psychological distress requires further elucidation. No previous study has examined
whether the latent patterns of aggression and psychological distress are the same in
male and female AAS users. Multigroup latent class analysis (MLCA) can be used to
classify individuals into groups based on their responses on a set of variables, and
to investigate measurement invariance across subgroups. We therefore conducted a
MLCA to identify discrete subgroups of aggression and psychological distress in AAS
users, and used measurement invariance to examine whether the identified subgroups
can be applied to both sexes. We also examined the relationship between sex and
subgroup belongingness. The sample comprised 206 AAS users (females = 58.30%)
aged 14–56 (mean= 26.86, SD= 7.12) years. They completed questionnaires assessing
demographics, AAS use, aggression, and psychological distress. Based on the MLCA,
five subgroups were identified: high aggression moderate distress users (HAMoD:
07.63%), moderate aggression distress users (18.64%), moderate direct aggression-mild
indirect aggression moderate distress users (22.95%), mild direct aggression-moderate
indirect aggression-distress users (11.71%), and low aggression mild distress users
(LAMiD: 39.06%). Although a homogenous five-class solution was the best model
for both sexes, sex was significantly associated with the probability of subgroup
membership. In particular, members of the HAMoD subgroup were more likely to be
male whereas members of the LAMiD subgroup were more likely to be female. Our
study provides novel empirical evidence of the idiosyncratic patterns of aggression and
psychological distress among male and female AAS users.
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INTRODUCTION
Anabolic-androgenic steroids (AAS) comprise testosterone and its synthetic derivatives. Due to
muscle mass building and strength enhancing properties AAS are typically used by elite athletes
and bodybuilders. The global lifetime prevalence of AAS use (1) is estimated at 3.3% with a higher
prevalence among males (6.4%) compared to females (1.6%).
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Despite experiencing aesthetic and performance benefits
(2, 3), users often report adverse physiological and psychological
effects (4–8), such as lack of impulse control, hostility,
and high levels of aggressive and violent behaviors (9–
11). Indeed, a recent meta-analysis of 12 randomized
controlled trials has shown that among healthy males,
AAS administration increases self-reported aggression (12).
However, considering the inconsistency of results across
studies (13–22) it is not clear whether there are unobserved
patterns of aggression and psychological distress among
AAS users.
Investigating subgroups of AAS users can facilitate the
identification of individuals and groups most sensitive to the
negative psychological consequences of AAS use, as well as
the development of targeted interventions (23, 24). Previous
studies on subgroups of substance users have mainly focused on
alcohol and tobacco use (25, 26). Still, few studies identifying
subgroups of AAS and appearance- and performance-enhancing
drug (APED) users have been conducted (27–30). However, no
previous study has examined subgroups of AAS users based
on their aggression and psychological distress profile, despite
these factors being strongly associated with AAS use (5, 12,
31, 32). A multigroup latent class analysis [MLCA; (33)] is
superior to traditional categorization of subgroups using cut-
off points (34). Hence, we conducted a MLCA which is a
powerful tool for classifying latent patterns of an observed
variable as well as examining group differences simultaneously
(33–35). We used the MLCA to identify subgroups of AAS
users and gender differences in identified subgroups based on
physical aggression, verbal aggression, anger, and hostility and
psychological distress patterns.
Moreover, AAS use is predominantly a male practice and AAS
use among females is an understudied area (1, 36). Relatedly,
the few studies that have examined the side effects of AAS use
among females are based on small samples (37–41). In addition,
males and females tend to use different doses and types of
AAS and believe that the doses and the types they choose is
best fitting to their sex (37, 42). More importantly, females
are an important group in clinical practice and policy making
on AAS use. Thus, information about patterns of aggression
and psychological distress in AAS-using females is important.
Accordingly, we included female AAS users in the current study
to identify their patterns of aggression and psychological distress
and to examine subgroups of female andmale AAS users.We also




Participants comprised 206 current AAS-using bodybuilders
(females = 58.30%) with a history of at least 6 months’
regular AAS use prior to data collection. Age of
participants ranged from 14 to 56 (M = 26.89, SD =
7.12) years. Other participant characteristics are presented
in Table 1.
TABLE 1 | Sample characteristics.




Range Mean (SD) Mean (SD) Mean (SD)
Age (years) 14–56 26.89 (7.12) 26.69 (6.72) 27.04 (7.44)
Height (cm) 154–192 171.54 (9.66) 180.46 (6.09) 165.11 (5.91)
Weight (kg) 45–170 71.53 (17.23) 84.64 (16.23) 62.06 (10.41)
Weight training
Total years 1–36 3.28 (4.02) 3.52 (4.96) 3.08 (3.04)
Days per week 1–7 3.40 (1.49) 3.97 (1.62) 2.97 (1.23)
Hours per week 1–20 5.12 (4.66) 6.19 (5.85) 4.37 (3.38)
AAS use duration (years) 1–3 1.33 (0.56) 1.51 (0.66) 1.19 (0.43)
N (%) n (%) n (%)
Highest education
High School 12 (5.80) 5 (5.80) 7 (5.80)
Diploma 35 (17.00) 16 (18.60) 19 (15.80)
Technician 20 (9.7) 8 (9.30) 12 (10.00)
Bachelor 92 (44.70) 39 (45.30) 53 (44.20)
Master 34 (16.5) 14 (16.30) 20 (16.70)
PhD 10 (4.9) 1 (1.2) 9 (7.50)
Marriage status
Single 153 (74.30) 67 (77.90) 86 (71.70)
Married 52 (25.20) 18 (20.90) 34 (28.30)
Work status
Full time 58 (28.20) 30 (34.90) 28 (23.30)
Part time 28 (13.60) 7 (8.10) 21 (17.50)
Self-employed 38 (18.40) 24 (27.90) 14 (11.70)
Unemployed 34 (16.50) 8 (9.3) 26 (21.70)
Student 40 (19.40) 14 (16.30) 26 (21.70)
Sports involvement
Competitive sport 6 (2.90) 4 (4.70) 2 (1.70)
Recreational sport 34 (16.50) 17 (19.80) 17 (14.20)
Competitive bodybuilding 30 (14.60) 10 (11.60) 20 (16.70)
Recreational bodybuilding 105 (51.00) 52 (60.50) 53 (44.20)
N n n
AAS type useda
Anadrol (Oxymetholone) 62 39 23








Durabolin 7 2 5
Equipoise (Boldenone) 12 8 4
Finajet (Trenbolone) 12 9 3
Maxibolin (Ethylestrenol) 2 2 0
Methyltestosterone 4 4 0
Primobolan 9 4 5
Stanozolol (Winstrol) 136 96 40
Steroid cocktail 3 1 2
Sustanon 44 21 23
Testosterone 114 66 48
aPercentages may not add up to 100% due to missing data on the respective items.
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Measures
Demographics
The questionnaire assessed demographic factors including age,
sex, weight, height, educational level, marriage, and job status.
Sports and Weight Training
We assessed participants’ main involvement in sports and
exercise as well as their total number of years of regular weight
training. We also asked participants how many times per week
(number of days and hours) they trained with weights.
AAS Use
Current AAS use was assessed with the question “Do you
currently use anabolic-androgenic steroids?” (yes/no). In
verifying AAS use, participants specified the AAS they used
(see Table 1). For the assessment of AAS use duration,
participants also indicated how long (years) they had been using
AAS regularly.
Aggression
We used the Short-Form Buss-Perry Aggression Questionnaire
[BPAQ-SF; (43, 44)] to assess aggression. Four items represent
physical aggression (e.g., “I have trouble controllingmy temper”),
three items assess verbal aggression (e.g., “I often find myself
disagreeing with people”), three items reflect hostility (e.g.,
“Other people always seem to get the breaks”), and two items
measure anger (e.g., “Sometimes I fly off the handle for no
good reason”). Items are answered on a 5-point Likert-type scale
ranging from 1 (Very unlike me) to 5 (Very like me). In the present
study, Cronbach’s α for physical aggression, verbal aggression,
hostility, and anger were 0.73, 0.70, 0.77, and 0.69, respectively.
Psychological Distress
We assessed symptoms of psychological distress (anxiety and
depression) using the Hospital Anxiety and Depression Scale
[HADS; (45, 46)]. HADS contains seven items reflecting anxiety
symptoms (HADS-A; e.g., “I feel restless as I have to be on the
move”) and seven items reflecting depressive symptoms (HADS-
D; e.g., “I have lost interest in my appearance”) experienced over
the last week. Items are scored on a 4-point scale (0–3). We
computed a composite score of anxiety and depression to indicate
psychological distress in general, adhering to previous studies
that have shown superior factor loadings of one general factor
(47, 48). Scores from HADS utilizing the general factor range
from 0 to 56. In the present study, Cronbach’s α for psychological
distress was 0.82.
Procedure
Eligibility criteria for participation were being a current: (1)
weightlifter and (2) regular AAS user for at least 6 months.
Participants were recruited from training centers and sports
supplement stores in Tehran, Iran. Data was collected via
personal meetings at the training centers and supplement
stores. All participants provided oral consent, participation was
voluntary and anonymous, and participants could withdraw
from participation. Upon participants’ consent, a trained
research assistant handed paper questionnaires to participants for
completion. Clarification about the questionnaire was provided
when necessary. No incentive or compensation was provided
for participation. Data was collected in June 2019. The study
was conducted in accordance with the Declaration of Helsinki.
Ethical approval was obtained from Alzahra University in
Tehran, Iran.
Statistical Analysis
Characteristics of the sample was determined in terms of
descriptive statistics as means and standard deviations for
interval and ratio level variables and by percentages for nominal
level variables. The major goal of the current study was to
examine patterns of aggression and psychological distress in male
and female AAS users, and to investigate whether the identified
patterns can be applied to both sexes. First, we conducted a Latent
Class Analysis [LCA; (49, 50)] to examine discrete patterns of
direct aggression (i.e., physical and verbal aggression), indirect
aggression (i.e., anger and hostility), and psychological distress
for the entire sample. In the context of present study, the
aforementioned indicators were used to estimate latent classes
of current AAS users. The Bayesian Information Criterion [BIC;
(51)] is the most commonly used fit criteria to select the optimal
number of latent classes (50, 52). Models with lower values of
information criteria have a better fit to the data (53). A common
approach is therefore to select the model with a number of latent
classes which shows the lowest BIC (54, 55). The likelihood-ratio
chi-square (L2) is a descriptive measure for assessing model fit
and when L2 is significant it shows that the model does not fit the
data. Entropy R2 and total proportion of adjacent classification
error were used as indicators of the quality of the classification.
Measurement invariance is required to determine whether the
identified latent classes can be applied to both sexes (53). Thus,
after selecting a latent class model for the entire sample, we tested
for measurement invariance across sex in order to make a valid
comparison across subgroups of male and female AAS users (55,
56).When comparing latent classes across groups, different levels
of homogeneity (i.e., measurement invariance) can occur, each
of which involves restricting specific sets of model parameters to
be equivalent in all groups. There are three prototypical models
that differ in the levels of measurement invariance (56). First is
the homogeneous model which assumes that the latent classes
have the same structure in each group. In this case effects of the
group variable on the indicator variables are completely mediated
by the latent classes. Hence, the homogeneous model imposes
restrictions on the measurement model without deteriorating the
fit with the data (Figure 1A).
Second is the partially homogeneous model where some of
the model parameters are restricted to be equal in all groups.
For example, when differences in answers of participants with
different sexes are not associated with differences in a latent
class, direct effects occur. Here, the goal is to examine whether
the group variable has a direct effect on the indicator variables
(Figure 1B). In addition, the heterogeneous model assumes that
the latent classes have different structures in each group. In
this unrestrictive model, the group variable has three sets of
effects including effect on latent classes, direct effect on indicator
variables, and interaction effects with latent classes on indicators.
Hence, a heterogeneous model lacks any comparability of results
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across groups as all measurement model parameters are group-
specific (Figure 1C).
To test measurement invariance, we conducted homogeneous,
partially homogeneous, and heterogeneous multigroup latent
class analysis (MLCA) with sex as the grouping variable.
Moreover, to relax the assumption of measurement invariance,
we assumed that some, but not all, indicators are invariant across
sex. We added the direct effect of the grouping variable on each
indicator (in the partially homogeneous model). The goal of this
step is to check the invariance of each indicator. See Figure 1 for
details. A MLCA approach is flexible in the sense that not all
latent classes need to be equivalent in order to validly compare
results across groups.
Next, for comparing and choosing the best model for
the data, we followed a model comparison procedure where
difference in likelihood-ratio chi-square (L2) with a difference
in degrees of freedom is used to determine which model is
most appropriate. We calculated the difference in L2 and in
degrees of freedom between consecutive nested models. The
unrestricted heterogeneous model served as the baseline for
this comparison. When moving from the homogenous model
to the unrestricted heterogeneous model, if the difference in
L2 between two consecutive nested models (i.e., one model
is obtained from a general model by imposing complex and
decreasing homogeneity on the former) is significant, the model
with more heterogeneity and less degrees of freedom fits the
data best (57). Finally, class proportions for each group were
examined. Here, participants were assigned to latent classes based
on the likelihood of belonging to a class using the proportional
assignment rule (57, 58). We used the Walt test to examine
the relationship between sex and class membership. Descriptive
analyses were conducted using RStudio version 1.1.463 (RStudio,




The average height (cm) and weight (kg) of female users were
165.11 (SD = 5.91) and 62.06 (SD = 10.41), respectively. Male
AAS users’ average height (cm) and weight (kg) were 180.46
(SD = 6.09) and 84.64 (SD = 16.23), respectively. Female and
male AAS users trained with weights, on average, 4.37 (SD =
3.38) and 6.19 (SD = 5.85) hours per week at the gym. The
average AAS use duration was 1.51 (SD = 0.66) years for males
and 1.19 (SD = 0.43) years for females. Oxandrolone (Anavar)
(males = 57, females = 55), testosterone (males = 66, females =
48), stanozolol (Winstrol) (males = 96, females = 40), Dianabol
(methandrostenolone) (males = 96, females = 33), and Anadrol
(oxymetholone) (males = 39, females = 23) were the most
used types of AAS among both sexes. See Table 1 for other
participant characteristics.
Patterns of Latent Classes and
Measurement Invariance
Fit statistics for the latent classes are presented in Table 2. A 5-
class solution was the best model as evident by the lowest BIC
FIGURE 1 | Three types of multiple group latent class models. (A)
Homogeneous model, (B) partially homogeneous model, and (C)
heterogeneous model.
Frontiers in Psychiatry | www.frontiersin.org 4 June 2021 | Volume 12 | Article 629428
Chegeni et al. Aggression and Distress in AAS Users
TABLE 2 | Fit statistics for the latent class analysis.
Model BIC (LL) N par L2 ACE (%)
1-class 4857.99 75 2878.33 0.00
2-class 4438.13 81 2426.71 0.01
3-class 4349.63 87 2306.45 0.02
4-class 4338.65 93 2263.71 0.03
5-class 4326.81 99 2220.11 0.02
6-class 4330.37 105 2191.91 0.03
BIC, Bayesian Information Criteria; N par, number of parameters in the model; L2, squared
log-likelihood; ACE, Adjacent Classification Error.
(4326.81). The squared log-likelihood (L2) was 2220.11 (p <
0.001), the total proportion of adjacent classification errors was
0.02, and entropy R2 was 0.94.
As the next step, considering the 5-class solution from the
initial Latent Class Analysis (LCA), we conducted a MLCA
to assess measurement invariance. Table 3 presents results of
the consecutive nested models. When comparing these nested
models, we found that sequentially adding direct effects of sex on
classes and the interaction between sex and classes did not lead
to a significant improvement of fit. Indeed, the 1L2 indicated
a deterioration of fit. Hence, the model comparison procedure
indicated that the homogeneous model fit was better than that
of all other models. Hence, sex did not affect measurement
variance. From Table 3, we can thus conclude that patterns of
aggression and psychological distress are not dependent on the
sex of AAS users.
We taxonomized the patterns of the five latent classes on
four risk categories: low, mild, moderate, and high. Accordingly,
class 1 (high aggression moderate distress users: HAMoD; 7.63%)
was characterized by the highest levels of direct (i.e., physical
and verbal aggression), indirect (i.e., anger and hostility), and
moderate psychological distress. Class 2 (moderate aggression
distress users: MoAD; 18.64%) comprised moderate levels of
direct and indirect aggression and psychological distress. Class
3 (moderate direct aggression-mild indirect aggression moderate
distress users: ModA-MiiA MoD; 11.71%) were characterized by
moderate levels of physical and verbal aggression, mild levels of
anger and hostility, and moderate psychological distress. Class
4 (mild direct aggression-moderate indirect aggression-distress
users: MidA-MoiAD; 11.62%) displayed mild levels of physical
and verbal aggression, moderate levels of anger and hostility
as well as psychological distress. Class 5 (low aggression mild
distress users: LAMiD; 39.06%) were characterized by lowest
levels of all the indicators of aggression and mild psychological
distress. Figure 2 presents the patterns of aggression and
psychological distress for the 5-class model.
In Table 4, we report the class proportions obtained from
the selected model. It can be seen that there was an inverse
proportional sex distribution of the subgroups. Specifically, the
proportion of male AAS users in class 1 (HAMoD) was 91.67%
while the proportion of female users was 08.33%. Also, class 2
(MoAD) consisted of 80.42% males and 19.58% females. The
third class (ModA-MiiA-MoD) included 32.46% of male AAS
users and 67.54% of female AAS users. Class 4 (MidA-MoiAD)
consisted of 30.00% of male AAS users and 70.00% of female
AAS users. Finally, the proportion of male users in the fifth class
(LAMiD) was 10.51% and the proportion of female users was
89.49%. Table 4 indicates results from Wald test. From Table 4,
sex was significantly related to class membership (Wald = 31.04,
p < 0.001) with members of class 1 (HAMoD) more likely to
be male (z = −5.02, p < 0.001) whereas members of class 5
(LAMiD) were more likely to be female (z = 3.51, p < 0.001).
DISCUSSION
The present study examined discrete patterns of AAS male and
female users based on measures of aggression and psychological
distress using a multigroup latent class analysis. We also
examined whether the identified patterns are applicable to
both sexes. Five latent classes offered the best explanation for
the patterns of physical aggression, verbal aggression, anger,
hostility, and psychological distress: high aggression moderate
distress (7.63%), low aggression mild distress (39.06%), moderate
aggression distress (18.64%), moderate direct aggression-
mild indirect aggression moderate distress (22.95%), and
mild direct aggression-moderate indirect aggression-distress
(11.71%). Altogether, the proportional distribution of the
identified subgroups indicates that while majority of AAS
users are characterized by low to moderate aggression and
psychological distress, about 8% display high aggression
with mild psychological distress. Moreover, the proportional
distribution denotes an idiosyncratic pattern of aggression and
psychological distress in the current AAS-using sample, in line
with previous indication from a study of APED users (60). The
distribution is also in line with findings from previous studies in
which AAS use had higher associations with increased hostility,
irritability, and anger rather than direct aggression (17, 60).
The observed subgroups of AAS users with different profiles
of aggression and psychological distress in the current study
adds support to a previous systematic review suggesting that
aggression and psychological distress are linked to AAS use but
not in all subgroups of AAS users (61).
Furthermore, results from the MLCA indicates that a
homogenous model is most appropriate when determining
male and female AAS users’ direct and indirect aggression
and psychological distress profiles. Inferably, AAS users’
belongingness to specific subgroups is not sex-determined
and the patterns of aggression and psychological distress
identified in the present study is applicable to both males and
females. Relatedly, the inverse proportional sex distribution
of the subgroups, with the highly aggressive subgroup having
significantly higher proportions of males whereas the low
aggression subgroup comprise of significantly higher proportions
of females, indicates that a higher proportion of males (compared
to females) are at an elevated risk of aggression and psychological
distress. This finding can also be explained by evidence of
earlier AAS use initiation, more extensive use (e.g., higher
weekly doses and higher number of AAS per cycle) as well as
a higher prevalence of stacking, polypharmacy and pyramiding
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TABLE 3 | Fit statistics of the estimated five-class multigroup latent class models.
Model BIC (LL) L2 df Comparison 1L2 Sig. result
Homogeneous model (HM) 4326.81 2220.11 100 — — —
Adding direct effect of sex on one indicator at a time
Physical aggression (PA) 4408.85 2500.22 88 HM vs. PA −148.40 Deterioration
Verbal aggression (VA) 4417.60 2445.45 76 HM vs. VA −145.99 Deterioration
Anger (A) 4412.08 2397.58 68 HM vs. A −144.70 Deterioration
Hostility (H) 4369.70 2291.68 56 HM vs. H −127.40 Deterioration
Partially homogeneous model (PHM) with all direct effects included 4411.33 2190.40 30 HM vs. PHM 29.71 Deterioration
Heterogeneous model (HeM) 2008.66 2315.42 75 HM vs. HeM −90.65 Deterioration
BIC, Bayesian Information Criteria; N par, number of parameters in the model; L2, squared log-likelihood; 1L2, difference in L2 between two consecutive nested model.
FIGURE 2 | Patterns of aggression and psychological distress in male and female AAS users.
in males compared to females (41). Importantly, the present
finding of an inverse proportional sex distribution of the
subgroups is consistent with evidence from a recent meta-
analysis of experimental studies showing that the association
between endogenous testosterone levels as well as testosterone
administration and aggression are stronger and significant in
males but not females (62).
The current study’s findings can inform preventive as well as
harm reduction and treatment interventions on AAS use, and
aggression and psychological distress. Preventive interventions
on AAS use incorporating education about the potential for
aggressive behavior and psychological distress may be beneficial
in reducing motivation and intention for AAS initiation (63–
65). Similarly, it is important that harm reduction and treatment
interventions for AAS use is extended into the amelioration
of aggression and psychological distress (64, 66, 67). In this
regard, the homogenous gender model identified in this study
underlines the indispensability of female AAS users in such
policy making particularly in relation to the tendency for
aggression and psychological distress. Furthermore, there is
a need for more refined approaches to treatment and harm
reduction in which the importance of AAS users’ different
profiles of aggression and psychological distress are taken
into consideration.
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TABLE 4 | Proportions of male and female AAS users in latent classes of aggression and psychological distress.
Sex HAMoD (%) MoAD (%) ModA-MiiA-MoD (%) MidA-MoiAD (%) LAMiD (%)
Male 91.67 80.42 32.46 30.00 10.51
Female 8.33 19.58 67.54 70.00 89.49
Total 07.36 18.64 22.95 11.71 39.06
Wald test§ −5.02* −0.52 1.19 1.76 3.51*
HAMoD, high aggression moderate distress users (07.63%); MoAD, moderate aggression distress users (18.64%); ModA-MiiA MoD, moderate direct aggression-mild indirect aggression
moderate distress users (22.95%); MidA-MioAD, mild direct aggression-moderate indirect aggression-distress users (11.71%); LAMiD, low aggression mild distress users (39.06%).
§Wald test: 31.04, p < 0.001; female = 1, male = 0; *p < 0.001.
The present findings should be interpreted in the context of
limitations such as our reliance on self-reports which can be
problematic for assessing substance use (68), and our inability to
draw causal inferences due to the cross-sectional survey design.
In the current study the average length of AAS use was 1.33
(SD = 0.56) years which equals, at least, two cycles of AAS
use (28). However, we do not know whether the participants
were “on cycle” or “off cycle” when participating in the data
collection. Moreover, the most popular AAS used by both sexes
were oxandrolone/Anavar, testosterone, stanozolol/Winstrol,
Dianabol/methandrostenolone, and Anadrol/oxymetholone in
line with evidence from previous studies (37, 69). From these
most frequently used types of AAS, only Anadrol (oxymetholone)
is anecdotally associated with increased aggression in humans
(70, 71). Hence, it is also plausible that factors such as
particular AAS, AAS use method (e.g., “blast and cruise,” “blitz-
cycles,” and “stacking”) and polypharmacy (28, 72) as well
as personality (73), AAS dependence and cognition (7), and
premorbidity such as structural brain abnormalities (6, 74)
account for the differences between the subgroups identified
in the present study and further studies are encouraged to
explore these.
Despite the abovementioned limitations, the current study has
some notable strengths. First, to our knowledge, the current study
represents a novel approach in examining discrete subgroups of
aggression and psychological distress among male and female
AAS users in particular. Another strength is our use of MLCA
in the identification of subgroups and role of sex as this method
is empirically superior to traditional categorization using cut-
off points (34). In addition, the preponderance of AAS research
so far has been conducted largely on male samples in Western
countries (3, 36). Further research using longitudinal designsmay
elucidate transitions between latent classes. An examination of
the psychosocial correlates of AAS users’ belongingness to the
subgroups identified in the present study may also be interesting.
Finally, it could be of interest to replicate these subgroups
and investigate the AAS types associated with members of
each subgroup.
CONCLUSION
Using MLCA, we investigated the patterns of male and female
AAS users’ aggression and psychological distress and whether the
identified patterns can be applied to both sexes. We identified
five discrete patterns of direct and indirect aggression and
psychological distress with about 8% displaying the highest levels
of aggression and mild psychological distress. Our findings also
indicate that patterns of aggression and psychological distress
are applicable to both male and female AAS users. Here,
members of the high aggression and moderate psychological
distress subgroup are more likely to be male whereas members
of the low, mild, and/or moderate aggression and psychological
distress subgroup are more likely to be female. Our study
provides pioneering empirical evidence of the unique patterns
of aggression and psychological distress among male and
female AAS users. Our findings can be useful for preventive,
harm reduction and treatment interventions on AAS use, and
aggression and psychological distress.
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